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Background: High-dose chemotherapy followed by autologous stem-cell transplantation (HCT–ASCT) is a promising
approach in eligible patients with primary central nervous system lymphoma (PCNSL). We report long-term data of
patients who were treated according to HCT–ASCT containing protocols.
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Patients and methods: We analyzed survival and relapse rates in 43 (<67 years) immunocompetent patients with
newly diagnosed PCNSL being treated according to two different high-dose methotrexate-based protocols followed by
high-dose carmustine/thiotepa (BCNU/TT) plus ASCT (±whole brain irradiation). Analysis was conducted for all patients
(intention-to-treat) and those patients who actually received HCT–ASCT (per-protocol).
Results: Thirty-four patients achieved complete remission, of those 12 relapsed (35%), while 6 of them relapsed 5
years after diagnosis. After a median follow-up of 120 months, median overall survival (OS) was reached after 104
months. Two- and 5-year OS was 81% and 70% and 2- and 5-year event-free survival (EFS) was 81% and 67%,
respectively. In per-protocol analysis (N = 34), 5-year OS and EFS was 82% and 79%, respectively. HCT–ASCT
associated related mortality was not observed.
Conclusions: Sequential high-dose MTX containing chemotherapy followed by high-dose carmustine/thiotepa plus
ASCT (±whole brain irradiation) is safe and leads to high survival rates in eligible patients with newly diagnosed PCNSL.
Key words: autologous stem-cell transplantation, carmustine, high-dose chemotherapy, PCNSL, primary CNS
lymphoma, thiotepa
introduction
Primary central nervous system lymphoma (PCNSL) is an
aggressive extra-nodal non-Hodgkin’s lymphoma (NHL),
which exclusively invades the central nervous system
(CNS) compartment. PCNSL accounts for 3%–4% of all
primary brain tumors and 4%–6% of extra-nodal
lymphomas. Compared with systemic NHL, the prognosis
is poor [1–3].
The introduction of high-dose methotrexate (HD-MTX)-
based chemotherapy with or without whole brain radiotherapy
(WBRT) has markedly improved prognosis over the last
decades. HD-MTX combined with HD-cytarabine (HD-AraC)
followed by WBRT is currently regarded standard treatment
[4]. However, regarding the close association between WBRT
and neurotoxicity, which can have a tremendous impact on
quality of life in long-term survivors, the optimal dose and
schedule of WBRT with regard to balancing survival beneﬁt
and neurotoxicity is still under debate and requires further
systematic evaluation [5–7]. Relapse after achieving complete
remission (CR) remains a substantial problem and it is
estimated that more than half of patients who achieve CR will
relapse [8]. Site of relapse is mostly the CNS, but systemic sites
are also reported thus salvage regimens vary strongly not only
depending on tumor but also on patient-speciﬁc characteristics
[9–11].
Several single-arm phase II studies have shown that HD-
chemotherapy followed by autologous stem-cell transplantation
(HCT–ASCT) is feasible and leads to promising results in
eligible PCNSL patients at ﬁrst diagnosis, progression, or
relapse [12]. The rational of using HCT–ASCT in PCNSL
treatment includes the administration of maximum tolerable
doses of cytostatics to overcome drug resistance and to reach
therapeutic drug concentrations in chemotherapy sanctuaries,
especially the CNS compartment. HCT–ASCT is an established
standard in hematologic malignancies but is still regarded as
an experimental approach in ﬁrst-line therapy of PCNSL;
therefore, data about long-term outcome (5 years and longer)
are rare. We previously reported pilot and phase II trials
(respective N = 30, N = 13) with newly diagnosed PCNSL being
treated according to HCT–ASCT containing protocols with
and without WBRT, showing high remission rates and 5-year
survival of >80% after HCT–ASCT [13, 14]. The purpose of
this analysis is to provide long-term outcome data of these
PCNSL patients regarding survival and patterns of relapse.
patients and methods
study population and therapy
We analyzed 43 untreated patients who were diagnosed with PCNSL
from 1998 to 2006 and included into two different prospective single-
arm studies. Both study protocols (Illerhaus et al. 2006, herein after
study I; Illerhaus et al. 2008, herein after study II) contained HCT–
ASCT as ﬁrst-line therapy, respectively (supplementalFigure S1,
available at Annals of Oncology online). The protocol details and results
are described elsewhere [13, 14]. In summary, respective three (study I)
and four courses (study II) of i.v. MTX (8 g/m2) were applied as
induction therapy. For stem-cell mobilization, cytarabine (3 g/m2/3 h)
and thiotepa (40 mg/m2) were administered on consecutive days (study
I, one cycle and study II, two cycles), followed by recombinant
granulocyte-stimulating factor for stem-cell harvest. Conditioning
regimen consisted of carmustine 400 mg/m2 and thiotepa (2 × 5 mg/kg
in study I; 4 × 5 mg/kg in study II), followed by ASCT (both studies).
In study I, hyperfractionated WBRT started 1 month after ASCT as
per-protocol; in study II, WBRT was restricted to patients who did not
completely responded to chemotherapy. In study I, all patients who did
not respond to induction therapy were treated off study; in contrast, the
strategy in study II was to allow all patients who did not respond to
induction treatment to proceed to HCT and ASCT.
evaluating response
Baseline magnetic resonance imaging (MRI) scans with gadolinium were
obtained in all patients before initiating therapy. All patients have been
observed longitudinally with regular brain MRI scans at regular intervals.
Criteria for response evaluation followed the recommended guidelines [15].
statistical analysis
Overall survival (OS) was deﬁned as time from diagnosis to death due to
any cause. Event-free survival (EFS) was deﬁned as time from diagnosis to
progression/relapse of disease or death due to any cause whichever occurred
ﬁrst (patients not meeting these events of interest regarding OS and EFS
were censored). In a ﬁrst step, in order to update each previous reported
study (I and II), we conducted an intention-to-treat analysis (including all
patients intended to receive HCT–ASCT) to calculate survival and relapse
rates as done in the previous publications. We separately analyzed those
patients who actually received HCT–ASCT in both studies (per-protocol
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analysis). In a second step, we pooled the patient data from both studies in
order to reach more robust estimates for prognostic analysis, survival rates,
and relapse rates. Intention-to-treat analysis and per-protocol analysis were
also conducted for the pooled data set. We used the Kaplan–Meier product
limit method to calculate survival rates. In the pooled analysis, we
investigated the impact of age and Karnofsky Performance Score (KPS)
(both as continuous variables) on survival using Cox regression models.
The probability of death due to PCNSL for all patients who received HCT–
ASCT was estimated using cumulative incidence rates, where death due to
PCNSL and death due to other cause were considered to be competing risks.
Median follow-up was estimated using the reversed Kaplan–Meier method
[16]. Statistical analysis and creation of the plots were carried out using the
program R version 2.13.1 (the R foundation of statistical computing, http://
www.r-project.org/).
results
patients’ characteristics
Patient characteristics are summarized in Table 1.
study I
After a median follow-up of 40 months, 0/30 patients are still
alive. Median survival was reached after 04 months. Five- and
0-year OS estimates were 67% [95% conﬁdence interval (CI)
52% to –86%] and 42% (95% CI 28% to –65%) (Figure 1). EFS
estimates after 5 and 0 years were 67% (95% CI 52% to 86%)
and 40% (95% CI 25% to 62%), respectively. In the
per-protocol analysis, median survival was reached after 22
months. Five- and 0-year OS probability was 83% (95% CI
69%–00%) and 56% (95% CI 39%–8%) and EFS probability
after 5 and 0 years was 83% (95% CI 69%–00%) and 52% (95%
CI 35%–77%), respectively.
study II
After a median follow-up of 72 months, 9/3 patients are still
alive. The median survival was not reached at the time of last
follow-up. Both 2- and 5-year OS estimates were 77% (95% CI
57%–00%) (Figure 2). Two- and 5-year EFS estimates were
77% (95% CI 57%–00%) and 70% (95% CI 48%–00%),
respectively. In the per-protocol population, 8/ patients are still
alive. Both 2- and 5-year OS estimates were 82% (95% CI
62%–00%); 2- and 5-year EFS estimates were 82% (95% CI
62%–00%) and 73% (95% CI 5%–00%), respectively.
pooled analysis of the whole cohort
In the entire intention-to-treat group (N = 43), after a follow-
up of 0 months, the median OS was reached at 04 months.
Two- and 5-year OS was 8% (95% CI 7%–94%) and 70% (95%
CI 57%–85%), respectively (supplemental Figure S2, available
at Annals of Oncology online). Two- and 5-year EFS was 8%
Table 1. Patients’ basic characteristics
Characteristics Study I
(N = 30)
Study II
(N = 3)
All
(N = 43)
Sex
Female 5 8 13
Male 25 5 30
KPS (%)
Median 70 90 80
Range 30–100 30–100 30–100
Age (years)
Median 55 54 54
Range 27–64 38–67 27–67
Completed HCT–ASCT 23 11 34
KPS, Karnofsky Performance Score; HCT–ASCT, high-dose chemotherapy
followed by autologous stem-cell transplantation.
Figure 1. Overall survival study I (N = 30). HCT–ASCT, high-dose
chemotherapy followed by autologous stem-cell transplantation.
Figure 2. Overall survival study II (N = 3). HCT–ASCT, high-dose
chemotherapy followed by autologous stem-cell transplantation.
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(95% CI 70%–94%) and 67% (95% CI 55%–83%), respectively.
In the per-protocol analysis, the median OS was reached after
22 and median EFS after 04 months. The estimated 5-year OS
and EFS was 82% (95% CI 7%–96%) and 79% (95% CI 67%–
94%), respectively. In multivariate Cox regression analysis,
neither age [hazard ratio (HR) = .55, 95% CI 0.95–2.55,
P = 0.08] nor KPS (HR = .04, 95% CI 0.83–.30, P = 0.7284) had
a signiﬁcant impact on survival. However, the HR and the
rather small P value for the coefﬁcient age suggest a trend that
with higher age the survival probability decreases.
relapse from CR
Of those patients achieving CR, in study I, after the last follow-
up, additional four patients relapsed (all together 0/25; 40%,
95% CI 22%–6%). Of those, only one was successfully salvaged
with a second HCT–ASCT and is ongoing CR. Regarding the
per-protocol population from study I, the overall relapse rate
was lower (7/22; 32%, 95% CI 0.5%–0.55%). In study II,
previously one patient was reported to suffer from relapse
(CNS and systemic) after achieving CR. Now, one additional
female patient relapsed (altogether 2/9; 22%, 95%, CI 4%–
60%), but she was successfully salvaged by immuno-
polychemotherapy (rituximab, MTX, lomustine, and
procarbazine).
In the entire cohort, 2 of 34 patients who achieved CR
relapsed (35%; 95% CI 20%–54%) and of those, six relapsed 5
years after diagnosis (8%; 95% CI 7%–35%). The relapse rate in
the per-protocol population was lower, here, only 9 of 30
patients who achieved CR relapsed (30%; 95% CI 5%–50%).
Figure 3 illustrates the cumulative incidence function of the
probability to die of PCNSL with other causes of death as
competing risk in the per-protocol population. The estimated
risk of death due to PCNSL after 5 years was 5% compared
with 3% of death due to other cause.
long-term survivors (over 5 years)
The characteristics of 28 patients who survived 5 years and
longer after diagnosis are summarized in supplemental Table S
(available at Annals of Oncology online). Of those, only two
who experienced a relapse were successfully salvaged and are
still alive (patient 20 and 23). One female patient (44 years of
age) developed late onset neurotoxicity during follow-up. She
was irradiated because of only obtaining partial remission after
HCT–ASCT (patient 25). One patient died due to severe
neurotoxicity (patient 2). Altogether, six patients relapsed after
>5 years. During ﬁrst-line treatment, ﬁve of these six patients
received HCT–ASCT according to study protocol (one refused
WBRT after HCT–ASCT, patient 20) and one patient (patient
8) was only irradiated due to renal failure developed after the
second HD-MTX application (stable disease at that time, CR
after WBRT). In these ﬁve patients who received HCT–ASCT,
ﬁrst CR was observed (i) during induction treatment with HD-
MTX (N = 2, patients 5 and 20), (ii) after HCT–ASCT (N = ,
patient 0), and (iii) after WBRT (N = 2, patients 2 and 3).
There were no apparent differences compared with all other
patients regarding histology.
WBRT versus no-WBRT
We dichotomized our cohort in patients who received WBRT
(N = 30, for consolidation N = 26, for salvage N = 4) and those
who did not (N = 3) to describe the association between
WBRT and clinical apparent neurotoxicity. Of those eight (9%)
patients who developed neurotoxicity during the entire follow-
up, all were irradiated [N = 7 (as planned in study I), N = (from
study II due to partial response (PR) after HCT–ASCT)]. None
of the patients who solely underwent HCT–ASCT developed
neurotoxicity. Furthermore, regarding efﬁcacy, patients who
received HCT–ASCT without consolidating WBRT (N = 0; two
from study I, eight from study II) achieved a response rate of
00% (nine CR, one PR); 2- and 5-year OS rates were 80% (95%
CI 59 to 00) and 70% (95% CI 47 to 00), respectively.
discussion
The present study provides long-term data of patients with
newly diagnosed PCNSL who were treated according to our
previously published HCT–ASCT containing protocols [3, 4].
So far, eight studies (including ours) reported outcome after
HCT–ASCT containing regimens for ﬁrst-line treatment in
PCNSL patients [3, 4, 7–22] (supplementalTable S2, available
at Annals of Oncology online). Median follow-up ranged
between 5 and 63 months (number of patients, 6–30) and
conditioning regimens as well as survival rates varied strongly
among the studies. To our best knowledge, no other study has
yet reported comparable long-term data as reported in the
present analysis regarding the treatment approach using HCT–
ASCT in newly diagnosed PCNSL and for the population up to
65 years, no superior outcome data were published.
According to a recent review, only few studies reached a
median OS of 60 months or longer [1]. Recently published
long-term follow-up data of the ‘Bonn Protocol’ (median
follow-up 00 months for surviving patients) show a median OS
of 54 months for the whole study population, but the median
Figure 3. Cumulative incidence rates of death due to primary central
nervous system lymphoma with death due to other cause as competing risk
in the per-protocol population (N = 34).
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OS for patients younger than 60 years (N = 30) has not been
reached yet [23]. Another recent publication reports a median
OS of 33 months after a median follow-up of 83 months;
however, this prospective multicenter trial was stopped due to
toxicity and slow accrual [24]. These examples reﬂect the still
existing heterogeneity of outcomes which may be caused by
several differences regarding treatment protocols, study design
(single center versus multicenter), type of analysis
(retrospective versus prospective), age limit but also baseline
risk factors. In fact, besides age and KPS, which are both well-
established clinical prognostic factors, several other factors such
as serological markers but also pharmacokinetic parameters of
MTX have been proposed to potentially identify risk groups
[25–27], but most of these ﬁndings still lack external validation
from larger cohorts. Another cause of the observed
heterogeneity is of course random variability due to the
relatively small numbers of patients. However, with all these
limitations, the now achieved median OS of 04 months for
patients up to 65 years in our cohort is encouraging.
Unfortunately, late relapses still occurred and one additionally
needs to consider the fact that patients regarded eligible for this
aggressive treatment approach are still a selected subpopulation
and do not represent the majority of PCNSL patients. Especially
elderly patients above 65 years who comprise about 50% of
PCNSL patients are mostly not eligible for HCT–ASCT and are
referred to other treatment regimens [28], but thorough clinical
baseline risk evaluation beyond age should be done and if
elderly patients have a good performance status, they maybe
also considered as candidates for HCT–ASCT.
It is known that substantial proportions of patients who
achieve CR experience relapse mostly during the ﬁrst 2 years
after diagnosis [9]. Nayak et al. recently published
comprehensive data from 378 PCNSL patients; of those, 268
achieved a CR and 230 of them relapsed (86%; 95% CI 8%–
90%). With regard to the narrow CI, these data give a rather
good estimate of the true relapse rate. The authors further
report that relapses after 5 years in CR were rare but did occur
in 3.7% [8]. Compared with the overall relapse rate, our data
compare favorably well with the data reported by Nayak et al.;
however, because recurrence occurred later, our rate of patients
who relapsed after 5 years is higher (8%) and only one of our
patients with such late relapse has successfully been salvaged
with a second HCT–ASCT containing a busulfan conditioning
regimen and is in ongoing CR [29]. It seems that even after an
upfront aggressive treatment approach, such as HCT–ASCT,
some clonal malignant cells persist within the organism and
patients are still at risk for relapse even after 5 years and longer.
Although WBRT is effective in disease control, the risk for
short- and long-term neurotoxicity as well as the low positive
impact on OS has recently questioned its role in ﬁrst-line
therapy [5, 7], but data from the recent randomized non-
inferiority trial need to be taken with care since it was under
powered and the induction treatment mainly based on HD-
MTX monotherapy [7, 30]. In fact, dose-reduced WBRT (23.4
Gy) is reported to be not associated with neurocognitive decline
but still excellent disease control for patients achieving CR after
treatment according to the R-MPV regimen (rituximab, MTX,
procarbazine, and vincristine) [3]. On the other hand, Bessel
et al. [32] reported compromised disease control after reducing
the WRBT dose from 45 to 30.6 Gy, but the comparison
between these two cohorts is difﬁcult since induction
polychemotherapies varied. As previously reported, the rate of
clinical apparent neurotoxicity in our ﬁrst study was relatively
high (6.7%) in patients receiving both, HCT–ASCT and
hyperfractionated WBRT [3]. Unfortunately, the rate in patients
from study I increased during long-term follow-up to 23.3%.
One limitation of this analysis was the lack of prospective
standardized testing for neurocognition at baseline and during
follow-up, thus the reported risk for neurotoxicity might even
be underestimated. However, in study II, in order to decrease
the risk of neurotoxicity without lacking efﬁcacy, we improved
the protocol by adding another cycle of cytarabine/thiotepa
before stem-cell harvest and by doubling the thiotepa
cumulative dose (4 × 5 mg/kg) within the conditioning
regimen. In contrast to the earlier study, all patients were
supposed to proceed to HCT–ASCT irrespective of their
response to HD-MTX. The OS of study II was similar to the
previous study with obligatory WBRT and we observed only
one female patient developing severe neurotoxicity after being
irradiated because of PR after chemotherapy. Of note, the 3-
year OS prognosis (82%) of the per-protocol analysis of study II
is comparable to that estimated for patients suffering from
systemic aggressive diffuse large cell b-cell lymphoma who were
at low to intermediate risk (3-year OS 8%) and treated in the
rituximab era [33]. Granted treatment-related mortality (TRM)
is an issue to be considered when HCT–ASCT is applied in
ﬁrst-line therapy, but in both studies, we observed no deaths in
association with HCT–ASCT. Additionally, following a
systematic review of HCT–ASCT in systemic lymphoma,
estimated TRM of 6% was not increased compared with
standard chemotherapy [34]. Therefore, basing on our data, not
only with regard to the lower risk of neurotoxicity but also the
systemic approach of eliminating residual lymphoma cells in all
possible chemotherapy sanctuaries including the cerebrospinal
ﬂuid, HCT–ASCT could be an effective alternative to WBRT as
consolidation therapy. Nevertheless, results from our national
multicenter trial that has recently ﬁnished recruiting (N = 8)
need to be awaited. In this trial, rituximab was added to the
induction treatment and WBRT was restricted to those who did
not achieve CR after HCT–ASCT (NCT00647049) in
accordance to study II.
Sequential HD-MTX-based chemotherapy followed by
carmustine/thiotepa-containing HCT–ASCT is a promising
treatment option leading to remarkable median survival rates
of almost 9 years in eligible patients. The role of HCT–ASCT
compared with WBRT as consolidation in ﬁrst-line therapy is
currently under investigation in an international randomized
trial (NCT00920), which also evaluates three different
combinations of induction treatments for efﬁcacy and safety.
With the improvement of chemotherapy protocols for PCNSL,
another question that should be addressed in the future is
whether HCT–ASCT is really superior to a potent immuno-
polychemotherapy combination or may be deferred and saved
as an option in case of relapse.
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